Bayer Pharma Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Healthcare Aktiengesellschaft

Bayer Schering Pharma Ag

Variagenics, Inc.

Bayer Aktiengesellschaft

Siemens Healthcare Diagnostics Gmbh

Axxam S.p.a.

Bayer Schering Pharma Aktiengsellschaft

Stefan Golz

Ulf Brüggemeier

Andreas Geerts

Eugene Vysotski

Svetlana Markova

Ludmila Frank

Bernd Kalthof

Philip Lienau

Volkhart Min-Jian Li

Ningshu Liu

Eckhard Bender

Franziska Siegel

Borries W Kemper

Holger Summer

Ludmila Burakova

Daniel Basting

Karl-Heinz Schlemmer

Dieter Lang

William Johnston Scott

Knut Eis

Ludwig Zorn

Kai Thede

Heinrich Meier

Martina Delbeck

Jens Ackerstaff

Detlev Sülzle

Ursula Mönning

Philipp Buchgraber

Barbara Albrecht-Küpper

Marcus Bauser

Andrea Hägebarth

Joachim Telser

Mario Lobell

Simon Holton

Frank Süβmeier

Jürgen Klar

Dirk Schneider

Florian Puehler

Hubert Trübel

Manfred Möwes

Anja Richter

Martina Klein

József Bálint

Peter Ellinghaus

Verena Vöhringer

Sonja Steppan

Wenlang Fu

Michaela Bairlein

Bernhard Weingärtner

Thomas Schlange

Verena Voehringer

Michael Böttger

Andreas Schall

Sarah Wagner

Rainer P Birkenbihl

Frank Süßmeier

Karin Birkenkamp-Demtroder

Hendrik Milting

Michael Seewald

Donatella D'Urso

Thomas Mondritzki

Sina Micus

Donatella D'urso

The present invention relates to substituted N-(phenyl-heteroaryl)-3-acetylamino-benzamides and N-[3-(acetylamino)phenyl]-phenyl-heteroaryl-carboxamides of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease such as cancer, wherein i.a.: Lrepresents an optionally substituted methylene or ethylene group; Lrepresents &#x2014;N(H)&#x2014;C(&#x2550;O)&#x2014; or &#x2014;C(&#x2550;O)&#x2014;N(H)&#x2014;; Rrepresents an optionally substituted 5- to 8-membered heterocycloalkyl, 4- to 10-membered heterocycloalkenyl, aryl, heteroaryl or &#x2014;N(R7)(Ci-C6-alkyl) group; Rrepresents an optionally substituted 5- or 6-membered heteroaryl group; Rrepresents an optionally substituted phenyl group. 

Compounds

The present invention relates to the use of cathepsin K and/or cathepsin S inhibitors in a method for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure.

Use of cathepsin K inhibition for the treatment and/or prophylaxis of pulmonary hypertension and/or heart failure

The present invention relates to amido-substituted azole compounds of general formula (I), in which X, X, R, R, R, R, Rand Rare as defined in the claims which are inhibitors of TNKS1 and/or TNKS2, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Amido-substituted azole compounds

The invention relates to the nucleotide and amino acid sequences, and to the activity and use, of the luciferases LuAL, Lu164, Lu16, Lu39, Lu45, Lu52 and Lu22.

Isolated luciferases and the use thereof

This invention relates to novel 5-[(hydroxymethyl)aryl]-substituted pyrrolo[2,1-f][1,2,4]triazin-4-amines of formula (I), to processes for the preparation of such compounds, to pharmaceutical compositions containing such compounds, and to the use of such compounds or compositions for treating angiogenesis-related disorders, in particular angiogenesis-related ocular disorders. 

Hydroxymethylaryl-substituted pyrrolotriazines as ALK1 inhibitors

The present invention is directed to a polynucleotide sequence of a novel acylglycerol acyltransferase-like protein MGAT-X1. The invention also provides the human MGAT-X1 associated with the dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases. The invention also provides assays for the identification of compounds useful for the modulation of dermatological diseases, urological diseases, muscle-skeleton disorders, hematological diseases, cancer, reproduction disorders, neurological diseases, metabolic diseases, cardiovascular diseases or gastroenterological diseases for treating of such diseases associated with expression of the MGAT-X1. The invention also features compounds which bind to and/or activate or inhibit the activity of MGAT-X1 as well as pharmaceutical compositions comprising such compounds.

Acylglycerol acyltransferase-like protein MGAT-X1 and uses thereof

The invention provides a human AdipoR1 which is associated with the cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, dermatological diseases, gastroenterological diseases, cancer, hematological diseases, inflammation, respiratory diseases, neurological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of AdipoR1 as well as pharmaceutical compositions comprising such compounds.

Diagnostics and therapeutics for diseases associated with G-protein coupled receptor AdipoR1(AdipoR1)

The invention provides LTBP2, which is associated with cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of LTBP2 as well as pharmaceutical compositions comprising such compounds. The invention also provides LTBP2 as a biomarker for diseases such as cardiovascular diseases, hematological diseases, neurological diseases, cancer, endocrinological diseases, and urological diseases.

LTBP2 as a biomarker and diagnostic target

The invention relates to the nucleotide and amino acid sequences and to the activity and use of the fluorescent protein CGFP.

[object Object]

The invention relates to the photoprotein mtClytin, to its nucleotide and amino acid sequences and to the activity and use of the photoprotein mtClytin.

Isolated photoprotein mtClytin, and use thereof

The invention provides a human NMU2 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NMU2 as well as pharmaceutical compositions comprising such compounds.

Diagnostics and therapeutics for diseases associated with Neuromedin U2 receptor (NMU2)

The invention provides a human HM74a which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of HM74a as well as pharmaceutical compositions comprising such compounds.

Methods of screening for potential therapeutics for diseases associated with G-protein coupled receptor HM74a

The present invention is directed to a polynucleotide sequence of a novel organic anion transporting (OAT)-like protein UST3-likel. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand. The invention also provides the human UST3-LIKE1 associated with the gastrointestinal and liver diseases, metabolic diseases, hematological disorders, respiratory diseases, neurological disorders, urological disorders and cardiovascular diseases as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling. The invention also provides assays for the identification of compounds useful for the modulation of said diseases. The methods of the invention involve cell-free and cell-based assays that identify compounds which bind to and/or activate or inhibit the activity of UST3-LIKE1, a organic anion transporting (OAT)-like protein, followed by an in vivo assay of the effect of the compound on said diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of UST3-LIKE1 as well as pharmaceutical compositions comprising such compounds.

Organic anion transporting (oat)-like protein UST3-LIKE1 and uses thereof

Growing community of inventors

Essen, Germany

Stefan Golz